Gilda Cuzzi
Overview
Explore the profile of Gilda Cuzzi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
48
Citations
1017
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Farroni C, Altera A, Salmi A, Vanini V, Cuzzi G, Arlehamn C, et al.
Front Immunol
. 2025 Jan;
15:1484143.
PMID: 39872515
Background: Subjects with immune-mediated inflammatory diseases (IMID), such as rheumatoid arthritis, with tuberculosis infection (TBI), have a high probability of progressing to tuberculosis disease (TB). We aim to characterize the...
2.
Najafi-Fard S, Farroni C, Petrone L, Altera A, Salmi A, Vanini V, et al.
Front Immunol
. 2024 Nov;
15:1411827.
PMID: 39530101
Objective: Cysteamine, a drug approved to treat cystinosis, has been proposed as a host-directed therapy for (Mtb) and SARS-CoV-2. The impact of cysteamine on the immune responses has not been...
3.
Petrone L, Peruzzu D, Altera A, Salmi A, Vanini V, Cuzzi G, et al.
J Infect
. 2024 Sep;
89(6):106295.
PMID: 39343243
Background: Identifying stage-specific antigens is essential for developing tuberculosis (TB) diagnostics and vaccines. In a low TB endemic country, we characterized, the Mycobacterium tuberculosis (Mtb)-specific immune response to a pool...
4.
Petruccioli E, Sbarra S, Vita S, Salmi A, Cuzzi G, De Marco P, et al.
Vaccines (Basel)
. 2024 Sep;
12(9).
PMID: 39339995
Background: Monkeypox (Mpox) is a zoonotic disease caused by monkeypox virus (MPXV), an Orthopoxvirus (OPXV). Since we are observing the first MPXV outbreak outside the African continent, the general population...
5.
Aiello A, Ruggieri S, Navarra A, Tortorella C, Vanini V, Haggiag S, et al.
Vaccines (Basel)
. 2024 Aug;
12(8).
PMID: 39204049
This study investigated the incidence and severity of SARS-CoV-2 breakthrough infections (BIs) and the time to swab reversion in patients with multiple sclerosis (PwMS) after the booster dose of COVID-19...
6.
Repele F, Alonzi T, Navarra A, Farroni C, Salmi A, Cuzzi G, et al.
Int J Infect Dis
. 2024 Mar;
141S:106999.
PMID: 38458427
Objectives: To investigate whether Mycobacterium tuberculosis (Mtb) DNA is detected in peripheral blood mononuclear cells (PBMC) of subjects with tuberculosis (TB) or TB infection (TBI) living in a low-burden country....
7.
Petruccioli E, Petrone L, Najafi-Fard S, Navarra A, Vanini V, Cuzzi G, et al.
Front Med (Lausanne)
. 2023 Dec;
10:1271632.
PMID: 38076244
Introduction: IFN-γ release assays (IGRAs) are one of the referral tests for diagnosing tuberculosis infection (TBI). To improve IGRAs accuracy, several markers have been investigated. Patients with immune-mediated inflammatory diseases...
8.
Picchianti-Diamanti A, Navarra A, Aiello A, Lagana B, Cuzzi G, Salmi A, et al.
Vaccines (Basel)
. 2023 Nov;
11(11).
PMID: 38006015
: We aimed to analyse the incidence and severity of breakthrough infections (BIs) in rheumatoid arthritis (RA) patients after a COronaVIrus Disease 2019 (COVID-19) vaccination booster dose. : We enrolled...
9.
Ruggieri S, Aiello A, Tortorella C, Navarra A, Vanini V, Meschi S, et al.
Int J Mol Sci
. 2023 May;
24(10).
PMID: 37239872
This study characterizes antibody and T-cell immune responses over time until the booster dose of COronaVIrus Disease 2019 (COVID-19) vaccines in patients with multiple sclerosis (PwMS) undergoing different disease-modifying treatments...
10.
Picchianti Diamanti A, Navarra A, Cuzzi G, Aiello A, Salemi S, Di Rosa R, et al.
Biomedicines
. 2023 Mar;
11(3).
PMID: 36979666
Data on the risk of adverse events (AEs) and disease flares in autoimmune rheumatic diseases (ARDs) after the third dose of COVID-19 vaccine are scarce. The aim of this multicenter,...